#Santé & Bien-être #Therapeutics
- Genomics
- Big data
- Artificial intelligence
- Network pharmacology
- Drug repurposing
- Molecule combinations
- Biomarkers
As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.
Discover >Genopole accompanies researchers, postdocs and start-up entrepreneurs through all the phases of their projects to ensure the best possible conditions for business development.
Discover >Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.
Discover >Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.
Discover >#Santé & Bien-être #Therapeutics
Pharnext develops new therapies and biomarkers based on network pharmacology with a proprietary discovery platform. The company is focused on pathologies with high unmet medical needs. These include neurodegenerative, orphan and common diseases (Charcot-Marie-Tooth disease Type 1A, Alzheimer’s disease, amyotrophic lateral sclerosis (ALS)).
BACKGROUND
Pharnext was founded by renowned scientists and entrepreneurs (including Professor Daniel Cohen, a pioneer in modern genomics) to develop new therapies targeting several key pathological mechanisms in severe orphan and common neurodegenerative diseases.
DESCRIPTION OF THE PRODUCTS / SERVICES / TECHNOLOGY
Pharnext’s approach is applicable to virtually any disorder and particularly suited to multifactorial diseases.
Pharnext is currently focused on neurodegenerative diseases:
CUSTOMER REFERENCES / COLLABORATIONS / HIGHLIGHTS
€91 million in equity raised from a foundation.
COLLABORATIONS SOUGHT
60 patent families
45 staff members
Strengths:
New paradigm in R&D for faster pharmaceutical developments, particularly in multifactorial diseases. Eminent scientists and breakthrough approaches in pharmacogenomics.
Innovation assets:
Innovative drug combinations based on genomic big data and artificial intelligence. Pharnext’s approach can potentially be applied to any disease.
In same field